KALA BIO (NASDAQ:KALA) Stock Price Down 0.8%

KALA BIO, Inc. (NASDAQ:KALA)’s stock price traded down 0.8% during mid-day trading on Monday . The company traded as low as $5.81 and last traded at $5.95. 8,097 shares were traded during trading, a decline of 92% from the average session volume of 101,337 shares. The stock had previously closed at $6.00.

Analysts Set New Price Targets

KALA has been the subject of a number of research analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of KALA BIO in a research note on Monday, August 19th. HC Wainwright dropped their target price on shares of KALA BIO from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, May 17th.

KALA BIO Price Performance

The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 1.97. The stock has a market cap of $27.71 million, a PE ratio of -0.40 and a beta of -2.12. The business has a fifty day simple moving average of $6.43 and a two-hundred day simple moving average of $6.73.

KALA BIO (NASDAQ:KALA) last announced its earnings results on Tuesday, August 6th. The company reported ($3.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.40) by $1.24. Research analysts forecast that KALA BIO, Inc. will post -11.76 earnings per share for the current year.

Insider Buying and Selling at KALA BIO

In other KALA BIO news, CEO Mark T. Iwicki sold 15,168 shares of KALA BIO stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total value of $72,048.00. Following the completion of the sale, the chief executive officer now owns 263,755 shares of the company’s stock, valued at approximately $1,252,836.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 23,984 shares of company stock worth $113,924. Company insiders own 13.40% of the company’s stock.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new position in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th biggest holding. SR One Capital Management LP owned 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by institutional investors.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.